Microdose Cannabis Extract Shows Promise in Slowing Cognitive Decline in Alzheimer's Patients
Key Insights
A Brazilian clinical trial found that daily microdoses of cannabis extract containing 0.3 mg each of THC and CBD stabilized cognitive function in 24 elderly Alzheimer's patients over 24 weeks.
Patients receiving the cannabis extract maintained their Mini-Mental State Exam scores while the placebo group showed cognitive deterioration, with cannabis users scoring 2-3 points higher.
The extremely low doses used in the study did not produce psychoactive effects or increase adverse events compared to placebo, addressing concerns about cannabis-related impairment.
A groundbreaking Brazilian study has demonstrated that microdoses of cannabis extract may help stabilize cognitive function in patients with mild Alzheimer's disease (search), offering new hope for addressing the growing global dementia (search) crisis. The research, published in the Journal of Alzheimer's Disease, represents the first successful clinical trial to test the microdose approach in Alzheimer's patients.
Study Design and Methodology
The randomized, double-blind, placebo-controlled trial, led by Professor Francisney Nascimento at the Federal University of Latin American Integration (search) (UNILA), enrolled 24 elderly patients aged 60-80 years diagnosed with mild Alzheimer's disease (search). Participants received either a daily cannabis extract containing 0.3 mg each of THC and CBD or a placebo over 24 weeks.
The cannabis extract was donated by ABRACE (search), Brazil's largest patient association, with no funding from cannabis companies. The researchers chose these sub-psychoactive doses specifically to avoid the "high" associated with recreational cannabis use while potentially maintaining therapeutic benefits.
Cognitive Stabilization Observed
After 24 weeks of treatment, patients receiving the cannabis extract showed stabilization in their Mini-Mental State Exam (MMSE) scores, while the placebo group demonstrated cognitive deterioration. The cannabis group scored 2-3 points higher than their placebo counterparts on the MMSE scale, which has a maximum score of 30 points.
"The impact was modest but relevant," noted the researchers, explaining that in patients with preserved or moderately impaired cognitive function, major changes within a few weeks may be unrealistic to expect.
Safety Profile and Limitations
The study found no significant differences in adverse events between the cannabis and placebo groups, likely due to the extremely low doses used. However, the cannabis extract did not improve other non-cognitive symptoms such as depression, general health, or overall quality of life.
The researchers acknowledged important limitations, including the small sample size and effects restricted to one dimension of the cognition scale. Despite these constraints, the work represents an unprecedented step in cannabis research for neurodegenerative diseases.
Scientific Rationale
The microdosing approach was inspired by previous research led by Andreas Zimmer and Andras Bilkei-Gorzo, who demonstrated in 2017 that very low doses of THC restored cognition in elderly mice. Their work showed that THC reversed gene expression patterns and brain synapse density in the hippocampus to levels similar to those of young animals.
Subsequent studies reinforced that the endocannabinoid system (search), which is important for neuroprotection and regulates normal brain activity, undergoes natural decline during aging. The researchers believe cannabinoids protect cognition by reducing drivers of inflammation in the brain.
Clinical Implications
The findings suggest that microdoses of cannabis can deliver therapeutic benefits while avoiding psychoactive effects, potentially opening doors to new formulations focused on prevention in vulnerable populations such as elderly people with mild cognitive impairment or family history of dementia (search).
The researchers described cannabis efficacy as superior compared to traditional Alzheimer's pharmaceutical therapies, though they emphasized the need for larger studies with longer follow-up periods and biological markers such as neuroimaging and inflammatory biomarkers to definitively answer whether cannabis can slow Alzheimer's disease (search) progression.